Journal Logo

PROGNOSTIC VALUE OF CLONAL HEMATOPOIESIS-MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE

PF227

Caprioli, C.1; Spinelli, O.1; Salmoiraghi, S.1; Intermesoli, T.1; Zanghì, P.1; Cavagna, R.1; Michelato, A.1; Buklijas, K.1; Elidi, L.1; Delaini, F.1; Oldani, E.1; Gianfaldoni, G.2; Bosi, A.2; Marmont, F.3; Audisio, E.3; Ferrero, D.3; Terruzzi, E.4; De Paoli, L.5; Rossi, G.6; Borlenghi, E.6; Cavattoni, I.7; Tajana, M.8; Scattolin, A. M.9; Mattei, D.10; Corradini, P.11; Campiotti, L.12; Ciceri, F.13; Bernardi, M.13; Todisco, E.14; Cortelezzi, A.15; Cortelazzo, S.16; Falini, B.17; Pavoni, C.1; Bassan, R.9; Rambaldi, A.1, 18; Lussana, F.1

doi: 10.1097/01.HS9.0000559124.85006.27
Poster Session I: Acute myeloid leukemia - Biology & translational research
Free

1Hematology and Bone Marrow Transplantation Unit, ASST Papa Giovanni XXIII, Bergamo

2AOU Careggi, Firenze

3AOU Città della Salute e della Scienza, Torino

4AO San Gerardo, Monza

5AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria

6ASST Spedali Civili, Brescia

7Ospedale San Maurizio, Bolzano

8ASST Ospedale di Cremona, Cremona

9Ospedale dell'Angelo e SS. Giovanni e Paolo, Venezia Mestre

10AO S. Croce e Carle, Cuneo

11Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

12Università dell'Insubria, Varese

13IRCCS Ospedale San Raffaele

14Istituto Europeo di Oncologia

15Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano

16Clinica Humanitas-Gavazzeni, Bergamo

17Università di Perugia, Perugia

18Department of Oncology and Hematology, Università degli Studi di Milano, Milano, Italy

Back to Top | Article Outline

Background:

Mutations in DNA and chromatin regulation genes have been associated with clonal hematopoiesis (CH) in older healthy subjects, but are also involved in leukemogenesis occurring as early events. In AML patients, the prognostic role of CH-mutations detected at diagnosis has been assessed mainly by investigating single mutations, with diverging results. Thus, the significance of pre-treatment CH-mutations as a group remains to be elucidated.

Back to Top | Article Outline

Aims:

To investigate the distribution and clinical impact of CH-mutations detected at diagnosis in AML patients with normal karyotype and treated with chemotherapy eventually followed by allogeneic hematopoietic stem cell transplant (alloHSCT) within the prospective NILG trial 02/06 [ClinicalTrials.gov Identifier: NCT00495287].

Back to Top | Article Outline

Methods:

Out of 572 newly diagnosed AML patients enrolled into the trial, 270 had a normal karyotype. For 213 of them, a molecular profile was obtained at diagnosis with standard approach and targeted NGS on peripheral blood and bone marrow samples. CH-mutations were defined as DNMT3A, TET2, ASXL1, IDH1 and IDH2. Based on the available data, 209 patients were re-classified as per the 2017 European Leukemia Net (ELN) guidelines. All patients were treated with intensive chemotherapy eventually followed by consolidative alloHSCT.

Back to Top | Article Outline

Results:

At least one CH-mutation was reported for 131 out of 213 evaluable patients (61.5%), while 82 patients had no CH-mutations (38.5%). Patients carrying CH-mutations were older in comparison with patients without CH-mutations (median age 53 vs 47 years, P = 0.0003). No preferential association was found in respect of AML type (i.e. de novo vs secondary AML, P = 0.25). The most recurrent CH-mutation was DNMT3A (83/131), followed by TET2 (32/131), IDH2 (26/131), IDH1 (20/131) and ASXL1 (18/131). A single CH-mutation was observed in 65% of patients, while 33.5% had a double mutation and 1.5% a triple mutation. Overall, CH-mutations were detected across all ELN risk groups. The likelihood of carrying a CH-mutation was significantly increased in patients with a NPM1 mutation (P < 0.0001), while the opposite was reported for patients with a biallelic CEBPa mutation (P < 0.0001). Taken together, CH-mutations did not affect the 5-years disease free survival (DFS) and overall survival (OS) (46% vs 54%, P = 0.45; and 50% vs 55%, P = 0.21). However, within the ELN risk categories, the presence of CH-mutations negatively affected the 5-years DFS (86% vs 59%, P = 0.03) and OS (86% vs 71%, P = 0.09) in patients in the favorable risk group, while these outcomes were not affected in the intermediate and adverse risk groups. By analyzing each CH-mutation separately, TET2 emerged as an independent risk factor for the achievement of CR [OR 0.25 (95% CI 0.08-0.7), P = 0.008], but not for OS [OR 1.56 (95% CI 0.89-2.75), P = 0.12]. Finally, 186 patients who received a consolidative alloHSCT in first CR were investigated, 107 of them carrying CH-mutations. AlloHSCT provided a significant benefit in terms of OS for the whole study population (P = 0.001), irrespective of the presence of CH-mutations (P = 0.87).

Figure

Figure

Back to Top | Article Outline

Summary/Conclusion:

CH-mutations are frequently detected at diagnosis in AML patients with normal karyotype across all ELN risk groups, but more likely in NPM1 mutated patients. Overall, the presence of CH-mutations is not associated with worse outcomes except for patients within the ELN favorable risk group. These findings suggest that an active search of these mutations might refine the risk of relapse in patients considered at favorable risk, while their role is limited in patients with more aggressive disease profile.

Copyright © 2019 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the European Hematology Association.